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1. INTRODUCTION 
 
The word mammal is derived from the Latin word “mamma” meaning breasts. Development of 
mammary glands represents a unique feature among this group and contributes to the superiority 
of this group of organisms in the phylogenetic tree. Apart from providing nutrition and immunity 
to the new born, breast milk has shown to be involved in neurological developmental process of 
the offspring (1). 
Inflammatory disorders of the breast are collectively known as mastitis. They not only cause 
morbidity to the mother but may also affect the structure, function of the mammary glands and 
breastfeeding practices. Hence, the duration of breast feeding, quality of breast milk, bonding 
between the mother and offspring are affected leading to deprivation of the protective effect and 
nutritional benefits of breast milk to the offspring. 
Mastitis may vary from acute mastitis, as described among lactating women (also known as 
puerperal or lactating mastitis) to chronic indolent mastitis such as Granulomatous mastitis. The 
former condition which is more common, is easily treatable and has a lesser propensity for 
recurrence and prolonged morbidity. The latter however tends to follow an indolent protracted 
clinical course resulting in significant morbidity. 
Granulomatous Mastitis is a chronic inflammatory condition affecting the mammary tissue 
which was first described in 1972 in Israel as a lesion mimicking breast carcinoma (2). Since its 
first description, there have been a number of isolated case reports and case series describing this 
entity from different parts of the world. Though it is a benign disease, unlike other forms of 
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mastitis, it has been found to have an indolent course. Patients most often present with multiple 
recurrences and relapses causing significant medical morbidity and psychological turmoil. 
Granulomatous mastitis presents as a wide clinical spectrum. In some patients, it presents only as 
a palpable breast lump which may be clinically indistinguishable from a malignant breast lump. 
On the other hand, it may present with overt signs of inflammation, as in other types of mastitis 
such as redness, warmth, tenderness, skin ulceration or multiple sinuses discharging pus. 
 
Thus, Granulomatous mastitis presents a diagnostic as well as therapeutic challenge to the 
treating physician. Furthermore, it continues to be an ill-understood disease. Initially described 
as a rare disease entity, the number of reported cases and published literature are on the upward 
trend which may probably due to under-diagnosis and underreporting of this condition. 
 
Most of the current literature on Granulomatous mastitis describes its clinical spectrum, 
diagnosis and management. There are very few studies that have been published about its 
etiopathogenesis resulting in an inadequate understanding of the disease and thereby a variety of 
theories of causation and therapeutic strategies. In a country like India, where infectious diseases 
are common, these patients are treated with prolonged antibiotic courses and empirical Anti-
tubercular therapy based on the granulomatous histopathology, with no microbiological evidence 
of infection with Mycobacterium species. 
 
Hence, an understanding of the causative factors and elucidation of the pathogenesis would help 
in defining the diagnostic criteria and formulation of better targeted therapeutic strategies and 
preventive measures to reduce the burden of this disease and its associated morbidity. 
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The increasing disease burden, the associated morbidity of this disease both to the mother and 
child and paucity of literature, especially from Asia and the Indian subcontinent led the 
investigators of this study to embark on this study. This study aims to analyze etiological factors 
which may be demographic, patient-related or environment-related and to test carefully for 
infection and autoimmunity that may play a role in causation of granulomatous mastitis. 
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2. AIMS AND OBJECTIVES 
 
AIM: To evaluate the possible etiopathology of Idiopathic Granulomatous Mastitis (IGM)  
 
PRIMARY OBJECTIVES: 
1. To test for uncommon infections in the breast as the cause of IGM by routine bacterial smear 
and culture, AFB smear and culture for typical and atypical mycobacteria and special tests for 
fungal etiology.  
2. To assess serum markers for autoimmunity (ANA, specific autoantibodies, Immunoglobulin 
levels) in patients with IGM.  
 
SECONDARY OBJECTIVES: 
1. To analyse demographics and clinical profile of patients with IGM. 
2. To analyse individual hormonal profile and breastfeeding practices as possible risk factors in 
IGM.  
 
STUDY HYPOTHESIS: Idiopathic granulomatous mastitis is a chronic inflammatory disorder 
of the breast that is mediated by an uncommon infection or autoimmune phenomenon.  
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Fig 3.1 A and B: Embryonic development of breasts 
3. REVIEW OF LITERATURE 
 
3.1 STRUCTURE AND FUNCTION OF MAMMARY GLANDS 
 
3.1.1 EMBRYOGENESIS OF MAMMARY GLANDS 
 
Mammary glands are essentially derived from modified, differentiated sweat glands. Around 4th 
to 6th week of gestation, mammary progenitor cells arise with proliferation of epithelial cells in 
the thorax. This, results in the formation of two ridges extending from the base of the upper limb 
bud, in the axilla to the base of the lower limb bud, in the inguinal region called the mammary 
ridges or milk lines. Majority of the mammary ridge eventually atrophies, except for a cluster of 
cells in the 4th intercostal space in the pectoral region which give rise to the primary mammary 
bud (Fig 3.1A and 3.1B) (3). 
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By the end of the first trimester, the primary mammary buds grow into the mesenchymal tissue, 
under the stimulation derived from mesenchymal regulatory factors (Fig 3.1C and 3.1D). 
Secondary mammary buds arise along the basolateral margin and continue to invaginate into the 
underlying mesenchyme to get surrounded by a zone of fibroblastic cells which differentiate to 
form fibroblasts, smooth muscle cells, capillary endothelial cells, and adipocytes (Fig 3.1E) (3). 
 
 
 
 
 
Branching and canalization of the secondary mammary buds result in the formation of lactiferous 
ducts. The epidermis forms a depression, known as the mammary pit during the third trimester 
which will give rise to the nipple-areolar complex (Fig 3.1F). Lactiferous ducts drain into 
retroareolar ampullae that coalesce at the mammary pit onto the skin. At the end of embryonic 
development, the term infant develops 15-20 lobes with a corresponding lactiferous duct opening 
out onto the overlying skin. 
Fig 3.1 C-F: Embryonic development of breasts 
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3.1.2 DEVELOPMENT OF MAMMARY GLANDS 
 
In the postnatal period, the infant breast shows features of both morphological and functional 
development which are signified by differentiation of glandular structures and development of 
the secretory epithelium respectively. The extent of development varies in the infant breast and 
has been elaborated by Anbazhagan et al (4). These changes may occur in varying proportions 
and does not follow a linear progression. The development of the mammary glands then enters a 
quiescent phase from 2 years of age till puberty.  
 
3.1.2.1 CHANGES IN PUBERTY 
 
At puberty, the breast undergoes modification both at morphological and ultra-structural levels 
which is influenced by various hormonal factors. Increasing secretion of follicle stimulating 
hormone and luteinizing hormone occurs under the stimulation from the hypothalamus. The 
increasing levels of hormones causes activation of primordial ovarian follicles and secretion of 
oestrogen. Oestrogen induces ductal development and branching apart from development of the 
connective tissue and vascularity. Lobular development takes place in the presence of increasing 
progesterone levels in the luteal phase of the menstrual cycle. Four different types of lobular 
development have been described. Type I lobules have a short terminal duct with a cluster of  
surrounding secretory cells called alveoli. Type II, III and IV lobules have a terminal duct 
branching into several ductules and an increasing number of alveoli. The nulliparous breast 
contains mainly type 1 lobules whereas the breast of women who have gone through pregnancy 
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and lactation has mostly type 4 lobules. The mammary glands stay inactive till pregnancy. 
Pregnancy brings about the next major change in the hormonal milieu. 
 
3.1.2.2 DEVELOPMENT AT THE CELLULAR LEVEL 
 
In the initial phase, there is increase in fibrous and fatty tissue within the stroma followed by 
elongation and branching of the ductal system. The epithelial layer develops into two layers, 
consisting of outer myoepithelial layer and inner luminal layer that can be further divided into 
ductal cells, lining the inside of the ducts, and alveolar cells, which secrete milk during lactation. 
 
Ductal elongation and branching results in formation of multiple segmental and sub-segmental 
ducts which arise from the primary bud. These sub-segmental ducts eventually branch to form 
terminal ducts and terminal ductules or acini. Group of acini along with surrounding interlobular 
stroma forms the Terminal duct lobular unit (TDLU) which is the functional unit of breast (5). 
Many other hormones such as insulin, prolactin, corticosteroids and growth hormone play a 
minor role in the overall development of breast. 
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3.1.2.3 DEVELOPMENT AT THE MORPHOLOGICAL LEVEL 
 
Morphological development of breasts in puberty begins at about 10 years of age. There is 
increase in breast tissue in the areolar region which gives rise to the primary breast mound (Fig 
3.2A). Elevation of the breast tissue with increasing protuberance of the nipple occurs by 12 
years of age (Fig 3.2B). Appearance of the secondary breast bud occurs by 14-15 years of age 
which is caused by accumulation of sub-areolar tissue (Fig 3.2C). The areolar tissue regresses in 
relation to the surrounding breast tissue giving rise to the adult contour of breast (Fig 3.2D).  
These changes have been described by Marshall and Tanner and have been formulated into a 
staging system known as Tanner’s staging (6). 
 
 
 
   
 Fig 3.2 A-D: Morphological development of breasts at puberty 
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3.1.3 GROSS AND ULTRASTRUCTURAL ANATOMY OF BREAST IN THE ADULT 
 
Mammary glands lie on both sides of the thoracic wall and extend from the second to sixth rib 
craniocaudally and from the lateral sternal border medially to the mid-axillary line laterally with 
extension into the axilla through the axillary tail of Spence. Breast tissue comprises varying 
admixture of both fatty and glandular tissue that depends on the age, breast volume, body mass 
and other factors. The nipple areolar complex is a hyperpigmented elevated area which serves as 
an outlet for milk production. The areola also has multiple modified sebaceous glands called 
Montgomery’s tubercles that help in lubrication of the areola during suckling (Fig 3.3) (3). 
 
 
 
The duct-lobular system of the breast comprises multiple lobes (15-20 in number) that are 
separated by fascia. Each lobe contains more than 40 lobules which in turn are comprised of 
almost 100 acini or alveoli. As described above, group of acini along with the surrounding 
Fig 3.3 Gross anatomy of breast 
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stroma forms the terminal duct lobular unit (TDLU) which is the basic secretory unit (Fig 3.4) 
(3). Eventually, secretions drain through lobar ducts into a lactiferous sinus which drains through 
the nipple. 
 
 
 
3.1.4 CHANGES IN PREGNANCY AND LACTATION 
 
During pregnancy, there is an increase in progesterone, placental sex steroids and other 
hormones such as placental lactogen and chorionic gonadotrophin which stimulates significant 
growth of lobulo-alveolar system. On microscopy, there is predominance of dilated alveoli and 
the two-layered epithelium changes to form a single layer within the alveolus. 
Fig 3.4 Ducto-lobular system (ETD- Extralobular terminal ductule; ITD – Intralobular terminal ductule) 
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The changes in the breast during pregnancy have been described below (3): 
Week of gestation Change 
0 Resting breast ~ 200 gm in weight 
1-4 Ductular sprouting/lobular formation 
5-8 Breast enlarges/vascular engorgement/areolar 
pigmentation/predominant lobular formation 
12 Large alveoli with single epithelial cell layer 
Beginning of colostrum formation 
>20 Alveolar dilatation/colostrum formation/ New 
capillary formation/myoepithelial cell 
hypertrophy 
Term 180% increase of mammary blood flow 
Weight approx. 400 g Fat droplet 
accumulation in alveolar cells 
 
 
 
 
Table 3.1 
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Prolactin levels gradually rise to reach peak levels at term and subsequently fall, with rise once 
breastfeeding is initiated. Galactopoesis or production of milk occurs due to these increasing 
levels of prolactin and the absence of inhibitory effect of placental sex steroids soon after birth. 
Emptying of the breast helps in continuation of galactopoesis. Stasis of milk for more than 48 
hours reduces milk secretion. 
During lactation, the upper part of the alveolar cell breaks away and changes from columnar to 
cuboidal in shape. Lactose synthesis and milk protein synthesis occurs by stimulation of lactose 
synthetase and nuclear RNA polymerase under the influence of prolactin. Proteins and fats are 
excreted by apocrine secretion whereas lactose is excreted by aprocine secretion and inorganic 
ions by active and passive transport. Thus, milk secretion occurs across the luminal cell 
membrane (“blood-milk barrier”). Following this, re-secretion of milk proteins and cells occurs 
leading to elongation of the alveolar cell. 
During the phase of weaning, involution starts in the breast. Reappearance of the characteristic 
two-layered alveolar epithelium occurs. There is increasing influx of histiocytes and 
lymphocytes that results in phagocytosis and apoptosis. The alveolar structures regress with 
preservation of the ductal structure. Despite this involution, there is some secretion that may be 
retained in the breast, even after lactation is stopped (7). 
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Fig 3.5 Histology of Lactating breast (Courtesy: Department of Anatomy, CMC, Vellore) 
Fig 3.6 Histology of Non-lactating breast (Courtesy: Department of Anatomy, CMC, Vellore) 
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3.2. INFLAMMATORY DISORDERS OF THE BREAST 
 
Mastitis denotes a group of inflammatory disorders involving the breast tissue.  The overall 
incidence and prevalence of mastitis is largely underreported as the numbers quoted in literature 
are only women seeking medical attention and disease definitions vary in different studies. Inch 
and Von Xylander et al in a meta-analysis have shown the incidence of mastitis to range from 
2% to 50% (8). In a prospective study done among 262 women from New Delhi, India in 2012, 
inflammatory disorders of the breast accounted for 10% of patients presenting to the out-patient 
clinic (9). 
Mastitis may be classified in many ways. They may be classified according to temporal profile 
into Acute and Chronic or based on their etiopathogenesis. In a review article published by 
Kamal et al, Mastitis has been broadly classified into infectious, non-infectious and malignant 
based on their etiopathogenesis (Fig 3.4) (10). 
The first group comprises simple mastitis (lactational or non-lactational), complex mastitis such 
as abscesses, infected cysts etc. and mastitis associated with specific diseases such as 
tuberculosis or fungal infections.  Out of 197 patients, 67% of patients belonged to this group, 
mostly involving lactating women (37.9%) (10). 
The second group comprises non-infectious conditions causing aseptic inflammation or chemical 
inflammation of the breast. This includes conditions such as periductal mastitis, idiopathic 
granulomatous mastitis, Plasma cell mastitis, diabetic mastopathy etc. and accounted for 27.4% 
of patients (10). 
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The third group comprises entities such as inflammatory breast carcinoma and malignant breast 
abscess which accounted for 5.6% (10) . 
 
 
 
 
 
 
This study focuses on Granulomatous mastitis and its etiopathogenesis. An understanding about 
this would be incomplete without an understanding of granulomatous inflammation in a broad 
perspective.  
	  Fig 3.7 Classification of mastitis 
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3.3. GRANULOMATOUS INFLAMMATION 
 
Chronic inflammation, as opposed to acute inflammation persists for a long duration, sometimes 
lasting weeks or months. This is understood as an attempt to contain an offending agent that is 
difficult to eradicate resulting in a process where inflammation, tissue injury and attempts at 
repair occur simultaneously. 
Granulomatous inflammation may be defined as a form of chronic inflammation which is 
characterized by macrophages, epithelioid cells and multinucleated giant cells which form a part 
of the mononuclear phagocyte system, along with lymphocytes, plasma cells and fibroblasts 
(11). They may be present in a diffuse manner or in the form of focal lesions called granulomas 
(Fig 3.10) (12). A detailed description of the different components of granulomatous 
inflammation is described below in an attempt to understand the pathophysiology. 
 
3.4 COMPONENTS OF CHRONIC GRANULOMATOUS INFLAMMATION 
 
3.4.1 MONONUCLEAR PHAGOCYTIC SYSTEM 
 
The circulatory cells which are derived from the hematopoietic stem cells in the bone marrow 
and progenitor cells from the yolk sac and liver of the developing fetus are known as monocytes. 
These cells migrate into tissues and differentiate to form macrophages. The progenitor cells from 
the fetus develop into resident macrophages, such as microglia, Kupffer cells, alveolar 
macrophages and macrophages in the spleen and connective tissues where they lie in the dormant 
state. In the setting of inflammation, these monocytes migrate to areas, which is governed by 
	   28	  
various chemotactic and activation mechanisms brought about by different chemical mediators 
and adhesion molecules (Fig 3.8) (12). 
 
 
 
 
 
Macrophages form the dominant cells in chronic inflammation. They ingest a wide variety of 
substances including microbes into membrane bound vacuoles by endocytosis. The macrophages 
then undergo activation followed by fusion of phagosome and lysosome allowing intracellular 
degradation and microbial killing. Microbial killing is done by superoxides, hydrogen peroxide 
and hydroxyl radicals and other microbicidal substances. The process is aided by the presence of 
antibodies. Digestion of particulate material and dead organisms is accomplished by lysosomes. 
Macrophage activation occurs by two different pathways resulting in different consequences 
(12). 
 
 
 
 
Fig 3.8 Mononuclear phagocytic system 
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3.4.2 CLASSICAL PATHWAY 
 
This pathway is brought about by microbial products such as endotoxins, by T cell–derived 
signals, importantly the cytokine IFN-γ in immune responses or by foreign substances including 
crystals and particulate matter. These cells also known as M1 macrophages, produce NO and 
ROS, upregulate lysosomal enzymes and secrete cytokines that stimulate inflammation. 
 
3.4.3 ALTERNATIVE PATHWAY 
 
This pathway is induced by cytokines other than IFN-γ, such as IL-4 and IL-13 which are 
produced by T lymphocytes and other cells. The macrophages activated by the alternative 
Fig 3.9 Pathways of macrophage activation 
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pathway are principally involved in tissue repair and not in inflammatory response. They secrete 
growth factors that promote angiogenesis, activate fibroblasts, and stimulate collagen synthesis. 
 
3.4.4 ROLE OF LYMPHOCYTES 
 
Macrophages have complex interactions with lymphoid cells at different phases of the immune 
response. Antigen presentation to the T lymphocytes and B-lymphocytes initiates cell-mediated 
immunity and helps in amplifying and propagating the inflammatory process.  These CD4+ T 
lymphocytes produce different types of cytokines that function differently(12): 
 
•   TH1 cells produce the cytokine IFN-γ, which activates macrophages by the classical 
pathway. 
•   TH2 cells secrete IL-4, IL-5, and IL-13, which recruit and activate eosinophils resulting in 
activation of the alternative pathway. 
•   TH17 cells secrete IL-17 and other cytokines, which induce the secretion of chemokines 
responsible for recruiting neutrophils and monocytes 
 
Lymphocytes and macrophages thus interact in a vicious cycle propagating chronic 
inflammation. Macrophages display antigens to T cells, express membrane molecules and 
produce cytokines that stimulate T-cell responses and activated T lymphocytes on the other hand 
produce cytokines which recruit and activate macrophages thus promoting further continuation 
of the inflammatory process (Fig 3.9) (12). 
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Thus macrophages play a central role in chronic inflammation by – Ingestion of microbes and 
devitalized tissue, secreting mediators of inflammation, displaying antigens to T-lymphocytes 
and responding to signals from T lymphocytes resulting in activation of cell mediated immunity 
(11). 
 
 
 
 
 
3.4.5 EPITHELIOID HISTIOCYTES 
 
Mononuclear cells with finely granular eosinophilic cytoplasm, vesicular nuclei, and indistinct 
cell boundaries usually noted in granulomas are known as Epithelioid histiocytes. Originating 
from the bone marrow, these cells mature into monocytes, which enlarge and enter peripheral 
circulation. When recruited into tissues, they are called as histiocytes. The activation of 
histiocytes, via the innate immune response, gives the cells their characteristic epithelioid 
Fig 3.10 Macrophage-Lymphocyte interaction  
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appearance (13). These epithelioid histiocytes are considered as specialized monocytes that are 
characteristic of granulomas(11). 
 
3.4.6 GIANT CELLS 
 
Multinucleated giant cells are commonly found in granulomas. They are formed by fusion of 
macrophages which may be caused by simultaneous phagocytosis by two or more macrophages. 
 
 
 
 
 
 
 
Fig 3.11 Tubercular granuloma with areas of central necrosis surrounded by 
multiple Langerhan type giant cells, epithelioid cells and lymphocytes 
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3.4.7 CLASSIFICATION OF GRANULOMATOUS INFLAMMATION 
 
As mentioned previously, Granulomatous inflammation ranges in a wide spectrum ranging from 
focal well-defined granulomas to diffuse inflammation. Focal granulomas are classified into two 
major forms – Foreign body granuloma and Immune granuloma. 
Foreign-body granulomas are granulomatous reactions to inert material like suture, talc, and food 
material without a T-cell immune response. A collection of histiocytes are found apposed to the 
surface of the foreign material as single histiocytes are unable to engulf the foreign material. The 
inert material can be visualized by light microscopy and often shows birefringence using 
polarized light. 
Immune granulomas induce a persistent T cell–mediated immune response in response to varied 
etiologies. They may further be classified into Necrotizing and Non-Necrotizing, suppurative and 
Histiocytic granulomas which is illustrated in the table below(13). 
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Table 3.2 Classification of Granulomatous inflammation 
	   35	  
3.5 ETIOLOGY OF GRANULOMATOUS INFLAMMATION 
 
Granulomatous  inflammation may be caused by a wide array of etiologies which include 
infectious, allergic, toxin-related, autoimmune, neoplastic or unknown etiology (13). 
 
3.6. GRANULOMATOUS MASTITIS 
 
3.6.1 HISTORICAL PERSPECTIVE AND DEFINITION 
 
In a case series published in 1972, Kessler and Wolloch from Israel described 5 cases of young 
women presenting within 5 years of childbirth, with a breast lump that was clinically suggestive 
of malignancy.  Histopathological analysis of these lesions showed presence of non-specific 
granulomas comprising giant cells and epithelioid histiocytes, confined to the lobules. They 
noted the distinct nature from other inflammatory mastitis, lack of response to antibiotics, 
response to steroid therapy and raised the possibility of auto-immune etiology. This was the first 
description of a newly described entity called Granulomatous mastitis (2). 
  
3.6.2 DISEASE BURDEN AND GEOGRAPHIC DISTRIBUTION 
 
The exact disease burden of granulomatous mastitis is difficult to ascertain as the number of 
reported cases vary and most of the published literature comprises of isolated case studies and 
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case reports. The annual prevalence of IGM was reported to be 2.4 per 100,000 women aged 20-
40 years, in a review article on Idiopathic Granulomatous mastitis among Hispanic women(14). 
Our literature search of PUBMED database using the keywords “Idiopathic granulomatous 
mastitis”, “Granulomatous lobular mastitis” and “Granulomatous mastitis revealed 348 published 
articles since its initial description in 1972. 
In a review article published in 2014 by Altintoprak et al, the distribution of large case series 
described in literature (1995-2014) was mostly from the Mediterranean and South Asian region 
(15). The most number of cases were reported from Turkey (>200 cases), followed by China and 
South Korea. Number of cases were reported from USA were 126 whereas France had the 
highest number of cases from Europe (55 cases). Total of 36 cases were reported from India. 
However, this distribution was not based on ethnicity and was rather based on purely geographic 
distribution. 
 
3.6.3 EPIDEMIOLOGY 
 
Though most commonly found in women, some cases of granulomatous mastitis in males have 
also been described. Granulomatous mastitis is most commonly found in young women of the 
childbearing age group, usually occurring within 5 years of childbirth(16–20). 
In a large multicentre retrospective study involving 720 patients published in 2017, mean age of 
patients was found to be 36 years (age range 32-42 years) (21). Omranipour et al, in a 
retrospective review of 43 cases in Iran, found patients with Granulomatous mastitis were within 
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an age range of 24-55 years with the mean age being 33.5 years (22).  In a retrospective review 
of 18 patients over a 25 year period, median age of patients was 36 years and 56% of these 
women were within 5 years of childbirth (23). 
 
3.6.4 ETIOPATHOGENESIS 
 
Granulomatous mastitis despite having been described four decades ago is not well understood. 
Its etiology and factors involved in its pathogenesis have not been completely studied or 
described in literature. 
Etiological factors that have been proposed include factors such as hormonal imbalance, 
autoimmunity, infections, α1-antitrypsin deficiency, smoking, ethnicity etc. (15). The three main 
hypothesis that have been proposed to explain its etiopathogenesis is Autoimmunity, Infections 
and Hormonal imbalance (24). 
 
3.6.4.1 AUTOIMMUNITY AND AUTOINFLAMMATION 
 
The most widely accepted etiological theory is autoimmunity.  It has been postulated that IGM is 
possibly caused by a localized (25) or systemic immune response. This in turn results in a state 
of autoinflammation. 
Autoinflammatory disorders are a distinct group of disorders with recurrent attacks of 
inflammation without any evidence of exposure to an auto-antigen (24). They may range from 
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syndromes presenting with recurrent fever to other disease such as Behcets syndrome, Crohn’s 
disease etc. They may be precipitated by a number of factors including environmental factors, 
psychological factors, trauma, immunization, cold exposure, and dietary indiscretion. Similarly, 
IGM is characterized by recurrent inflammation of the breast tissue which is characteristic of 
autoinflammatory disorders. 
Omranipour et al postulated a hypothesis that extravasation of milk into the interstitial tissue 
triggers a localized immune response that results in granulomatous inflammation (Fig 3.11) (22). 
 
 
 
 
There have been various reports of patients with IGM presenting with extra-mammary 
manifestations such as erythema nodosum,  polyarthritis etc. (26–30). In a retrospective analysis 
of IHC data from biopsy of 18 patients with IGM, Erhan et al, reported T-cell predominance in 
14 patients and presence of B-cells in 7 patients (19). 
Breast tissue hypertrophy and increased fragility. 
(Caused by pregnancy, lactation, hyperprolactineima, OCPs 
etc.) 
Breast microtrauma, milk stasis and interstitial 
extravasation 
Induction of autoimmunity, recurrent inflammation and 
relapses 
Fig 3.12 
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Evaluation of serological markers has also been done in patients with IGM. Ozel et al analyzed 
Rheumatoid factor (RF), Antinuclear Antibodies (ANA) and Anti-DsDNA in 8 patients with 
IGM which showed 6 patients positive for RF and 2 patients positive for ANA and Anti-DsDNA 
(31). In a study by Altintoprak et al, 26 patients with IGM were studied for serum ANA and 
extractable nuclear antibodies – 9 patients were found to be ANA positive at 1:100 dilution (32). 
The use of immunosuppressants like corticosteroids, methotrexate, azathioprine etc. in the 
management of IGM also lends support to the possibility of an autoimmune etiopathology (33–
35). 
 
3.6.4.2 MICROBIOLOGICAL AGENTS 
 
Several authors have investigated the hypothesis that Granulomatous mastitis may be caused by 
infectious agents that cause chronic, indolent and persistent infection in the breast tissue. The 
spectrum of causative organism includes Bacterial, Mycobacterial, Fungal and Parasitic 
organisms.  
 
BACTERIAL ORGANISMS 
 
Thornton et al, in a study assessing the endogenous flora of the human breast found that 53% of 
specimens obtained from 231 cultures were positive for coagulase-negative staphylococcus. 
Aerobic bacteria such as Diphtheroids, Lactobacillus, D-Enterococcus, Micrococcus, Alpha-
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haemolytic Streptococcus and anaerobic organisms such as Propionibacterium acne, Peptococcus 
and Clostridium sporogenes were most commonly cultured (36). 
Taylor et al showed the presence of Corynebacterium in 34 patients with IGM(37). Subsequent 
studies by Paviour and other authors showed presence of Corynebacterium species(38). In a 
metagenomic review published by Hai-jing Yu et al, 13 out of 19 patients with IGM grew 
Corynebacterium, the predominant organism being Corynebacterium kroppenstedtii (39). 
However, there is difficulty in differentiating if the presence of these organisms in culture 
signifies, contamination, colonisation or true infection. Large case series have not shown 
significant growth of bacterial organisms. Retrospective analysis of 66 patients presenting to 
Department of Endocrine Surgery CMCH, Vellore from 2011-2015 showed growth of 
Coagulase-negative Staphylococcus aureus in 8 patients and Enterococcus, Citrobacter diversus 
and Staphylococcus aureus in 1 patient each (Unpublished data). 
 
MYCOBACTERIAL ORGANISMS  
	  
Propensity for mycobacterial organisms to cause chronic granulomatous inflammation has led to 
the proposition that Mycobacterial organisms may be involved in the etiopathogenesis. Incidence 
of tuberculous mastitis accounts for less than 1% and less than 0.1% of benign breast lesions. 
Mycobacterium tuberculosis is the most common organism, however, atypical mycobacteria 
have been found in isolated cases (40). In retrospective data from our institution from 2011-
2015, 1 out of 66 patients grew Mycobacterium chelonae (unpublished data). 
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FUNGAL ORGANISMS AND PARASITES 
	  
There have been very few published case reports on growth of fungal and parasitic organisms in 
Granulomatous mastitis. Blastomycosis, Cryptococcosis, Histoplasmosis, Actinomycosis and 
filarial organisms such as Wuchereria bancrofti have been described to cause granulomatous 
inflammation in breast tissue(15,41–45).  In our retrospective analysis, there were no patients 
who grew fungal organisms or showed presence of parasitic organisms. 
 
3.6.4.3 HORMONAL IMBALANCE 
 
Prevalence of the disease most commonly among young women, especially within 5 years of 
childbirth and recent history of lactation has given rise to the theory of hormonal imbalance 
being a possible etiological factor in Granulomatous mastitis.  
The breast is increasingly being considered as an endocrine organ, in its current context. This 
organ, not only undergoes dynamic change during different phases of the menstrual cycle but 
also undergoes numerous structural and functional changes during pregnancy and lactation. As 
described above, estrogen and progesterone are important for development of the ductal and 
lobular system respectively.  While estrogen has a tendency to promote mitoses and 
proliferation, progesterone has a biphasic effect- initially promoting mitosis and subsequently 
slowly down the same by causing cell cycle arrest in early G1 phase. Proliferation of breast cells, 
increase in breast volume, size, increase in vascularity, increase in secretion etc. are few of the 
changes that may cause increased propensity to breast infections and mastitis. 
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OCPs cause prolongation of cellular proliferation, thereby leading to a hypothesis of possible 
etiological role in IGM. Definitive causative association with OCP intake has been questioned by 
several authors. In a study by Al-Khaffaf et al, 18 patients with Granulomatous mastitis were 
analyzed and history of OCP intake was found in 27.7% (23). Asoglu et al studied 18 patients 
with Granulomatous mastitis and 22.2% showed history of OCP intake (17). However, Baslaim 
et al in a review of 20 patients showed no use of OCPs (18).  
As suggested by Omranipour et al, hormonal alterations due to various factors such as 
pregnancy, lactation, use of oral contraceptive pills (OCP) etc. has been thought to increase 
breast secretions and alter the breast tissue environment, thereby making it prone for 
extravasation of intraluminal contents causing a local autoimmune phenomenon resulting in 
granulomatous inflammation.  
However, occurrence of disease in non-lactation women and in male breasts has led to the 
conclusion that hormonal factors may not be solely responsible. 
 
3.6.4.4 SMOKING 
 
Some authors believe that granulomatous mastitis has similarities to periductal mastitis and may 
even be considered as components of the same pathology. Pathogenesis of periductal mastitis has 
been attributed to stagnation of secretions within the ductal system due to either squamous 
metaplasia or duct dilatation which may occur as part of aberrations of normal development. 
This causes periductal inflammation and duct fibrosis causing extravasation of intraluminal 
contents into the interstitial tissue. This subsequently leads to bacterial colonization. 
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Smoking as an etiological risk factor has been extensively studied in periductal mastitis. Shafer 
et al showed that the relative risk of developing recurrent subareolar breast abscess was 9.2 (3.6-
23.5) for a light smoker and 26.4 (9.9-70.2) for a heavy smoker (46).   
Heavy smokers were more likely to harbour anaerobic bacteria and also have a higher degree of 
squamous metaplasia in the ducts. Toxic products have also been seen in secretions in smokers. 
These may cause extravasation of intraluminal secretions as there is a greater propensity for duct 
epithelial damage facilitating extravasation. Anti-estrogenic effect of smoking also has been 
postulated to cause earlier menopause and inhibit growth of Gram-positive bacteria thus 
facilitating growth of anaerobic bacteria.   
However there has been no definite association between smoking and granulomatous mastitis. 
Al-Khaffaf et al showed history of current smoking in 17% of patients with IGM as compared to 
60% in periductal mastitis group. 22% of patients with IGM had past history of smoking as 
compared to 69% in periductal mastitis group (23). Asoglu et al showed 77% (14/18) patients 
with history of nicotine addiction (17). Baslaim et al did not have any patients in their series with 
history of smoking (18). In a large case series of 720 patients published by Uysal et al, 24% of 
patients had history of smoking (21). 
 
3.6.4.5 HYPERPROLACTINEMIA 
 
Elevated prolactin levels have been found to play a role in inflammation, fibrocystic changes, 
ductal ectasia, benign breast lesions, IGM and even in the development of breast carcinoma. 
There have been case reports of patients with hyperprolactinemia, either due to pituitary 
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adenoma or drug-induced, presenting with IGM(47–51). Hence hyperprolactinemia has been 
postulated to play a probable role in its etiopathogenesis. 
 
3.6.4.6 ETHNICITY 
Altintoprak et al looked at the worldwide distribution of IGM cases published in literature. This 
showed a predominance of cases in the Mediterranean and South East Asian regions (15). This 
peculiar distribution of cases has given rise to an epidemiological conundrum of the possibility 
of ethnicity or any common environmental exposure that may be responsible in disease 
causation.  
 
3.6.4.7 MISCELLANEOUS 
 
In a case report by Schelfout et al, the authors demonstrated Alpha-1 anti-trypsin deficiency (52). 
Alpha-1 anti-trypsin is a protein that is synthesized in the liver. It is a serine-protease inhibitor 
that prevents activation of protease and helps in control of inflammation. Deficiency of this 
protein has been attributed to the cause of inflammation in a number of inflammatory diseases 
like bronchiectasis etc.  
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3.6.5 CLINICAL PRESENTATION 
 
Granulomatous mastitis has a wide spectrum of clinical presentation.  The disease occurs most 
commonly in women, though few cases of male patients have been described in literature (53). 
Though there is a wide age range of patients, most common age group affected is second to 
fourth decade (15,18–23). The most common presentation is an ill-defined firm mass in the 
upper outer quadrant of the breast in a young woman with recent childbirth or lactation. As 
described in the index case report, it commonly mimics malignancy and is often diagnosed after 
a core biopsy for suspected malignancy. Patients may often present with signs of inflammation 
such as warmth, erythema, tenderness, ulceration of overlying skin with pus discharge and 
multiple discharging sinuses (Fig 3.6). In the case series published by Kiyak et al, 66.6% of 
patients presented with inflammatory signs. Axillary lymphadenopathy was seen in 42% (54).  
 
 
Fig 3.13 Clinical photograph of IGM with signs of inflammation and multiple sinus tracts 
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3.6.6 DIAGNOSIS – IMAGING AND PATHOLOGY  
 
Radiological evaluation of women with granulomatous mastitis maybe done by Ultrasound or 
Mammogram. Larsen et al retrospectively analysed the imaging characteristics in 54 women 
diagnosed with granulomatous mastitis. The most common ultrasound feature was irregular 
hypoechoic mass associated with multiple tubular hypoechoic structures (59%). Features of skin 
edema, thickening and sinus tracts are also encountered in 52%. Axillary lymphadenopathy was 
seen in 28%. 
The most common mammogram feature was large focal asymmetric density (44%) with axillary 
lymphadenopathy in 18% and skin thickening in 7%(55). Though radiological features may often 
be equivocal and non-contributory, mammogram and ultrasound are often the first step in work 
up of patients with granulomatous mastitis. Features suspicious of malignancy on imaging 
warrant further evaluation with histopathology. 
Diagnosis of granulomatous mastitis is confirmed by histopathology with tissue obtained either 
by excision or core biopsy. Inflammation in granulomatous mastitis is predominantly localised to 
the regions of the lobules (14). Histopathology shows granulomas with Langerhans giant cells, 
epithelioid histiocytes surrounded by lymphocytes. Presence of non-caseating granulomas 
composed of epithelioid histiocytes and multinucleate giant cells is characteristic of idiopathic 
granulomatous mastitis as compared to Tubercular mastitis where there is caseous necrosis. 
Inflammatory cells such as neutrophils, plasma cells and lymphocytes is present. Special staining 
for acid fast bacilli (Ziel Neelsen staining) and fungal organisms (PAS, Giemsa) are often 
negative ruling out infective causes. Tissue culture for Bacterial, Mycobacterial, Fungal 
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organisms may also be used as an adjunct to rule out infectious etiology.  Presence of acini and 
other lactational changes may be found in certain regions. Occasionally, there may be dilated 
ducts with periductal or intraductal inflammation. In a clinicopathological study of 26 patients, 
by Tse et al observed granulomas in all patients. 17 patients had Langerhans giant cells and four 
showed foreign body giant cells. Majority of the inflammatory cells were lymphocytes (>65%) 
(16).  
Confluent granulomatous lesions may result in the formation of micro abscesses. Occasionally, 
there are microcystic space that are noted in the centre with no secretions. Neutrophils may be 
found within the space or outlining it.  
 
 
 
*	  
Fig 3.14 *Lobulocentric granulomatous inflammation – Low magnification 
(Courtesy: Department of Pathology, CMC, Vellore) 
	   48	  
 
 
 
 
 
 
Fig 3.15 Perilobular inflammation with multinucleate giant cells, epithelioid histiocytes and lymphocytes among 
acini (Courtesy: Department of Pathology, CMC, Vellore) 
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3.6.7 MANAGEMENT 
 
Both medical and surgical therapy or a combination of both are recommended for management 
of granulomatous mastitis. Localized lesions with no signs of skin changes or sinuses are 
amenable to wide local excision of these lesions. Extensive abscess formation, presence of 
complex sinuses and skin involvement is often managed medically initially or with a 
combination of both. Surgical excision in these conditions are more prone for recurrence and do 
not provide cosmetically acceptable results after debridement or excision. 
Corticosteroids are the principal form of medical therapy. Described in 1980 by Dehertogh et al, 
steroid therapy has caused a paradigm shift in management of granulomatous lesions from 
completely surgical to primarily medical (34). Though initial authors prescribed larger doses of 
steroids for shorter durations, it is now recommended to use smaller doses for steroids for longer 
periods lasting 3-6 months to reduce recurrence of disease. Other immunosuppressive agents 
such as Methotrexate, Azathioprine etc. may also be used in steroid resistant cases. Fig 3.14 
represents a treatment algorithm for granulomatous mastitis (56). 
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Fig 3.16 Diagnostic and treatment algorithm 
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4. MATERIALS AND METHODOLOGY 
 
The study was conducted after obtaining approval from the Institutional Review Board and 
Ethics Committee of Christian Medical College, Vellore. 
Study Design 
 The study was designed as a prospective case control model.  
Inclusion Criteria 
1.   Cases: All patients diagnosed with Granulomatous Mastitis based on histopathology 
from either core biopsy or excision biopsy. 
2.   Controls: Normal women without Granulomatous Mastitis who have been group 
matched with individual cases for age (Age +/- 5 years) and childbirth (Last childbirth <5 
years). 
Exclusion Criteria 
1.   Patients with histopathology other than Granulomatous Mastitis. 
2.   Patients not consenting to be part of the study. 
Study population 
Cases and controls were recruited from the Outpatient department and wards of Department of 
General Surgery, Endocrine Surgery and Obstetrics & Gynecology. 
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Informed Consent Administration 
Both cases and controls were given an information sheet with details about the study in English 
and in translated versions in Tamil, Telugu, Hindi and Bengali. Informed consent was taken by 
the principal investigator from the patient after being given adequate opportunity to read the 
information sheet and ask questions. 
 
Methodology of Data collection: 
Data collection was done solely by the principal investigator. All patients with a clinical 
suspicion of Granulomatous mastitis underwent core biopsy. Samples were obtained for both 
histopathology as well as cultures. All cases and controls satisfying inclusion criteria, after 
obtaining informed consent underwent a one-on-one interview by the principal investigator with 
the help of a structured, validated questionnaire detailing the patient demographics, clinical 
profile and presence of risk factors. Subsequently, serum sample was obtained from them and 
was analyzed for the following  
1.   Serum Anti-Nuclear antibody (ANA) 
2.   Serum Prolactin 
3.   Serum Globulin 
If the patient was ANA positive, the sample was further processed for specific autoantibody 
analysis. Similarly, if the globulin levels were elevated, the sample was further processed for 
analysis of Immunoglobulin levels (IgA, IgM, IgG). 
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Methodology of Laboratory analysis: 
1.   Serum ANA estimation was done by indirect immunofluorescence using fluorescein 
coated antibodies to human IgG (EUROIMMUNE, Germany) for both cases and 
controls. 
2.   Serum specific autoantibody estimation was done by Enzyme linked Immunosorbent 
Assay only in the cases, if Serum ANA was positive.  
3.   Serum globulin levels was derived from A/G ratio (Albumin measured by Bromocresol 
green dye binding colorimetric assay and total Protein measured by biuret method) for 
both cases and controls. 
4.    Immunoglobulin levels was estimated using immunoturbidometry in both cases and 
controls, if serum globulin levels were elevated.   
5.   Serum prolactin was estimated using sandwich immunoassay in both the cases and 
controls.   
6.   Tissue taken at the time of core biopsy or excisional biopsy was sent for Bacterial, 
Fungal, MGIT culture and Gene XPERT TB PCR 
 
Interpretation of results: 
1.   Serum ANA was considered positive if indirect immunofluorescence showed 
fluorescence intensity more than 2+ at a dilution of 1:100. If serum ANA was positive, 
specific autoantibody analysis (Eg. AntiSm, AntiRo, AntiLa) was done based on pattern 
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of immunofluorescence.  
2.   Serum globulin more than 3.5 gm/dl was considered as elevated and serum IgM, IgA and 
IgG estimation was done. Serum immunoglobulin levels above the upper limit of normal 
range was considered as elevated (IgA - >420 ng/ml; IgG - >1700 ng/ml; IgM - >190 
ng/ml). 
3.   Serum prolactin was considered as elevated if levels were more than 25 mg/dl. 
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5. STATISTICAL METHODS 
 
 
Sample size calculation 
Assuming power of the study is 80%, confidence interval of 95%, proportion of ANA positives 
in comparison group is 5%, using the formula,  
n= (r+1/r) (p*) (1-p*) (Zß +Zœ/2)2 ÷ (p1-p2)2  
p1 - Proportion of cases with ANA positivity 
p2 - Proportion of controls with ANA positivity 
Zœ/2 - Standard normal variate for level of significance  
Zß - Standard normal variate for power  
r - Proportion of cases to controls  
p* = p1 + p2 ÷ 2  
Two-sided confidence level(1-alpha)     95 
Power (% chance of detecting)      80 
Ratio of Controls to Cases       1 
Hypothetical proportion of controls with exposure (57)(58)  5 
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Hypothetical proportion of cases with exposure(32)   35 
Least extreme Odds Ratio to be detected:     10.23 
 
Category Kelsey(59) Fleiss(60) Fleiss with CC 
Sample size cases* 28 27 34 
Sample size controls* 28 27 34 
Total sample size* 56 54 68 
 
CC – Continuity correction 
* Results from OpenEpi, Version 3, open source calculator--SSCC  
Data Entry and Analysis 
Data collected from all cases and controls were entered using EpiData Manager and EpiData 
Entry Client (v4.2.0.0). Analysis was done using STATA Data analysis and statistical software 
(v13.1). 
All demographic and clinical variables were summarised as counts and percentages for 
categorical variables, mean and standard deviation for symmetrically distributed continuous 
variables and median and range for skewed continuous variables.  
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Chi square test was used to compare the proportions between categorical variables. The 
Independent t-test was used to compare the means between two groups for normally distributed 
continuous variables and the Mann-Whitney U test was used for skewed variables. For all data 
analysis, 5% level of significance was considered to be significant.  
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6. STUDY ALGORITHM 
 
  
Fig 6.1 
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Fig 6.2 
Fig 6.3 
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7. RESULTS 
 
The total number of cases of histologically proven Granulomatous Mastitis recruited in the study 
period from May 2016 to August 2017 (1 year and 3 months) was 30 cases. As detailed in the 
study algorithm, 30 normal women who were matched for the same age group (+/- 5 years) and 
last child birth (+/- 5 years from last child birth) were recruited as controls. 
Category Number of patients (n) 
Cases 30 
Controls 30 
 
 
PATIENT DEMOGRAPHICS 
 
All cases and controls in this study were females. Mean age of patients in the case group was 
33.76 years (Range 23-62 years) whereas in the control group it was 33.86 years (Range 21-65 
years). 
Variable Case (Mean +/- S.D) Control (Mean +/- S.D) p value 
Age 33.76 +/- 7.68 33.86 +/- 9.23 0.9638 
Table 7.1 
Table 7.2 
	   61	  
 
 
 
 
 
0
10
20
30
40
50
60
70
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
Ag
e	  
(y
ea
rs
)
Cases
Age	  distribution	  -­‐ Cases	  
0
10
20
30
40
50
60
70
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
Ag
e	  
(Y
ea
rs
)
Controls
Age	  distribution	  -­‐ Controls
Fig 7.1 
Fig 7.2 
	   62	  
 
Majority of the patient population was Indian except for two patients from the case group and 
three patients from the control group who hailed from Bangladesh. 
Distribution of patient population affected by the disease was mostly from West Bengal 
accounting for 43.3% as shown below.  
 
 
 
 
 
West	  Bengal,	  
43.33%
Tamil	  Nadu,	  10%
Andhra	  Pradesh,	  
13.33%
Jharkhand,	  
13.33%
Kerala	  ,	  3.33%
Odisha	  ,	  6.67%
Assam,	  3.33%
Meghalaya,	  3.33%
State	  of	  Origin	  -­‐ Cases
Fig 7.3 
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State Cases Controls Total 
West Bengal 13 (43.3%) 5 (16.67%) 18 (30%) 
Tamil Nadu 3 (10%) 18 (60%) 21 (35%) 
Andhra Pradesh 4 (13.3%) 2 (6.67%) 6 (10%) 
Jharkhand  3 (10%) 0 3 (5%) 
Kerala 1 (3.33%) 2 (6.67%) 3 (5%) 
Odisha 2 (6.67%) 0 2 (3.33%) 
Assam 1 (3.33%) 0 1 (1.67%) 
Meghalaya 1 (3.33%) 0 1 (1.67%) 
Other country 2 (6.67%) 3 (10%) 5 (8.33%) 
Total 30 30 60 
Pearson Chi2 p value –0.004 
 
 
INFECTIOUS ETIOLOGY 
Six cases showed growth in bacterial culture. However, there was no growth noted in MGIT or 
Fungal culture and no patients showed positivity on Gene XPERT TB PCR. 
Bacteria cultured include Coagulase negative staphylococcus aureus (CONS) (n=5) and 
Methicillin Resistant Staphylococcus Aureus (n=1).  CONS was considered to be a skin 
contaminant with no pathological significance. 
 
Table 7.3 
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 Bacterial Culture MGIT Culture Fungal Culture Gene XPERT TB PCR 
No. of cases 
positive 
6 0 0 0 
 
 
 
 
 
 
CONS
83%
MRSA
17%
Bacterial	  organisms
Table 7.4 
Fig 7.4 
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AUTOIMMUNE MARKERS 
Only one patient in our cases series was Serum ANA positive whereas all controls were ANA 
negative. This patient was however previously diagnosed with Rheumatoid arthritis and was on 
treatment for the same with oral steroids, Methotrexate and Leflumide. Specific autoantibody 
analysis was not done due to inadequacy of the sample. 
13 out of 30 cases had an elevated Serum Globulin level as compared to 7 out of 30 controls. 
Further Serum Immunoglobulin level analysis was done for these patients. IgM levels were not 
elevated in any of the cases, however, one patient from the control group had an elevated IgM 
level. None of the cases or controls had elevated IgG or IgA levels. 
 
 
 
Positive
3%
Negative
97%
Serum	  ANA
Variable Case (Mean +/- S.D) Control (Mean +/- S.D) p value 
Serum Globulin level 3.4 +/- 0.67 3.26 +/- 0.36 0.9531 
Fig 7.5 
Table 7.5 
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HYPERPROLACTINEMIA 
None of the patients in the case or control group were lactating at the time of recruitment. Three 
patients in the case group had serum prolactin level > 25 ng/ml. Among the control population, 
one patient had elevated serum prolactin level. Two sample Wilcoxon rank-sum (Mann-whitney) 
test was used for analysis which did not show any statistically significant difference between 
cases and controls. 
 
 
 
 
 
 
 
 
 
Variable Case [Median (IQR)] Control [Median (IQR)] p value 
Serum Prolactin level 9.06 (6.80, 15.50) 7.40 (5.40,10.20) 0.1086 
Table 7.6 
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Fig 7.9 
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ANALYSIS OF OTHER RISK FACTORS 
 
SOCIOECONOMIC STATUS 
Majority of patients in both the case and control group belonged to the upper and upper-middle 
socio-economic scale (Modified Kuppusamy scale)(61). There was no statistically significant 
relationship between socio-economic status and disease (Pearson Chi2 p value – 0.891) 
 
SES Cases Controls 
Upper 12 (40%) 12 (40%) 
Upper middle 10 (33.33%) 8 (26.67%) 
Lower middle 4 (13.3%) 4 (13.3%) 
Upper lower 4 (13.3%) 6 (20%) 
Lower 0 0 
Pearson Chi2 p value – 0.891 
Table 7.7 
	   70	  
 
 
 
 
Upper
40%
Upper	  middle
34%
Lower	  middle
13%
Upper	  lower
13%
Lower	  
0%
SES	  -­‐ Cases
Upper
40%
Upper	  middle
27%
Lower	  middle
13%
Upper	  lower
20%
Lower	  
0%
SES	  -­‐ Controls
Fig 7.10 
Fig 7.11 
	   71	  
BREASTFEEDING PRACTICES 
Patients in the case group had breastfed at least one child (Range 1-4, Mean 1.6) whereas one 
patient in the control group did not breastfeed both her children. There was no difference 
between cases and controls, in terms of number of children breastfed.  
 
 
 
 
 
	  
 
 
 
 
	   
 
All cases had breastfed in the past (All lactations) for an average duration of 25.74 months 
(Range 5-60 months). The mean duration of last breastfeeding amongst cases was 25.16 months. 
On the other hand, patients belonging to the control group had breastfed for an average duration 
of 15.27 months (Range 3-39 months) with mean duration of last breastfeeding being 15.45 
months. This seemed to be a statistically significant difference between cases and controls (Two 
sample t-test p value = 0.0002; 0.0006)  
Variable Case (Mean +/- S.D) Control (Mean +/- S.D) p value 
Number of children 
breastfed 
1.6 +/- 0.77 1.7 +/- 0.83 0.6319 
Average duration of 
breast feeding (All 
lactations) 
25.74 +/- 11.71 15.26 +/- 8.37 0.0002 
Average duration of 
last breast feeding  
25.16 +/- 11.62 15.44 +/- 8.62 0.0006 
Table 7.8 
	   72	  
None of the cases or controls were currently breast feeding. Average duration since last 
breastfeeding was 52.8 months in cases as compared to 67.9 months in controls. 
66.6% of cases and 75.8% of controls always breastfed adequately. Equal number of cases 
breastfed on demand (50%) and periodically (50%). Amongst controls, the periodicity of breast 
feeding was similar (46.4% vs 53.6%). There was no difference between cases and controls in 
terms of adequacy and periodicity of breastfeeding. 
Variable Subgroup Cases Controls Pearson Chi2 p 
value 
Adequacy of 
breastfeeding 
Always  20 (66.67%) 22 (75.86%) 0.144 
 Almost always 5 (16.67%) 7 (24.14%)  
 Occasionally  3 (10%) 0  
 Never 2 (6.67%) 0  
Periodicity of 
breastfeeding 
On demand 15 (50%) 13(46.43%) 0.786 
 Periodical 15 (50%) 15 (53.57%)  
 Every 2 hours 12 (80%) 12 (75%( 0.137 
 5-10 times/day 3 (20%) 1 (6.25%)  
 < 5 times/day 0 3 (18.75%)  
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Most of the cases (90%) and controls (96%) breastfed on both sides. Amongst the cases, one 
patient exclusively breast fed on the left (reason unknown) and two patients exclusively 
breastfed on the right (Due to retracted left nipple and feeling of inadequate milk production and 
poor suckling by the infant on the left breast). All these three women had disease on the 
contralateral side. As mentioned above, one patient in the control group did not breastfeed both 
her children. However, there was no statistically significant difference between cases and 
controls in this aspect (Pearson Chi2 p value – 0.217). 
 
 
Bilateral	  
90%
Left	  
3%
Right
7%
Side	  of	  breastfeeding	  -­‐ Cases
Variable Subgroup Cases Controls Pearson Chi2 p value 
Side of breastfeeding Bilateral  27 (90%) 29 (100%) 0.217 
 Left 1 (3.33%) 0  
 Right 2 (6.67%) 0  
Fig 7.12 
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Use of breast pump and expression of milk was found in 20% of cases and 13.79% controls 
which was not statistically significant (Pearson Chi2 p value – 0.525). Prevalence of lactation 
related problems such as cracked nipple, mastitis/breast abscess and breast engorgement was 
analyzed. Cracked nipple was reported by 13.33% of cases as compared to 6.9% in controls 
(Pearson Chi2 p value – 0.413). Mastitis/breast abscess was reported by 10% of cases as 
compared to 6.9% in controls (Pearson Chi2 p value – 0.669) and breast engorgement in 16.67% 
cases as compared to 10.34% in controls (Pearson Chi2 p value – 0.478). There was no 
statistically significant difference in lactation-related problems between cases and controls. 
Variable Cases Controls Pearson Chi2 p 
value 
Use of breast 
pump 
6 (20%) 4 (13.79%) 0.525 
Use of expressed 
milk 
6 (20%) 4 (13.79%) 0.525 
Cracked nipple 4 (13.33%) 2 (6.9%) 0.413 
Mastitis/Breast 
abscess 
3 (10%) 2 (6.9%) 0.669 
Breast 
engorgement 
5 (16.67%) 3 (10.34%) 0.478 
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43.33% of women in the case group washed hands before breastfeeding as compared to 72.41% 
among the control group. This difference was found to be statistically significant (Pearson Chi2 p 
value – 0.024). 60% of women in the case group cleaned the breast before breastfeeding 
compared to 72.41% of women in the control group. However, this difference was not 
statistically significant (Pearson Chi2 p value – 0.314). 
Variable Cases Controls Pearson Chi2 p 
value 
Washing hands before 
breastfeeding 
 13 (43.33%) 21 (72.41%) 0.024 
Cleaning breast before 
breastfeeding 
18 (60%) 21 (72.41%) 0.314 
 
 
 
CLOTHING HABITS 
Only two patients each in the case and control group reported non-usage of brassiere (6.67%) 
which did not seem to have a significant difference between cases and controls. 93.33% of 
patients in both the groups did not have history of any allergic reaction to clothing.  
Source of water for washing clothes was from borewell in 46.67% (60% in controls) and Public 
water supply in another 46.67% (33.33% in controls) of cases. (Pearson Chi2 p value – 0.76) 
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Variable Subgroup Cases Controls Pearson Chi2 p 
value 
Usage of Brassiere Daily  20 (66.67%) 24 (80%) 0.580 
 Only outside 
the house 
7 (23.33%) 3 (10%)  
 Occasionally 1 (3.33%) 1 (3.33%)  
 Never 2 (6.67%) 2 (6.67%)  
Hours of usage Always 6 (21.43%) 10 (35.71%) 0.621 
 < 6 Hrs 6 (21.43%) 4 (14.29%)  
 6-12 Hrs 2 (7.14%) 1 (3.57%)  
 >12 Hrs 14 (50%) 13 (46.43%)  
Frequency of 
change 
Daily 26 (96.30%) 28 (100%) 0.304 
 Once in 2-3 
days 
1 (3.70%) 0  
Fitting Loose 3 (10%) 1 (3.57%) 0.337 
 Fitting 24 (85.71%) 27 (96.43%)  
 Tight 1 (3.57%) 0  
Allergic reactions 
to clothing 
 2 (6.67%) 2 (6.67%) 1.00 
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Variable Subgroup Cases Controls Pearson Chi2 p 
value 
Source of water 
for washing 
Borewell 14 (46.67%) 18 (60%) 0.761 
 Public water supply 14 (46.67%) 10 (33.33%)  
 Reservoir 1 (3.33%) 1 (3.33%)  
 River 1 (3.33%) 1 (3.33%)  
 
 
LOCAL APPLICATION OF SUBSTANCES 
There was history of regular application of substances such as talcum powder, oil, moisturizer, 
deodorant/perfume over the breast in 36.67% of cases as compared to 20% in controls. (Pearson 
Chi2 p value – 0.152). Only one patient in the case group reported allergic reaction following 
usage of deodorant. 
TRAUMA 
Three patients gave history of trauma to the breast in the case group. There was no history of 
trauma to the breast in any of the controls.  This difference was not statistically significant. 
(Pearson Chi2 p value – 0.076). 
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Variable Cases Controls Pearson Chi2 p value 
Local application 11 (36.67%) 6 (20%) 0.152 
Trauma 3 (10%) 0 0.076 
 
 
DIETARY HABITS 
Both case and control groups predominantly consumed non-vegetarian diet. Predominant type of 
meat consumed was chicken in 78.57% of cases and 57.14% controls (Pearson Chi2 p value – 
0.053) with 60.7% patients (cases and controls) consuming meat less than twice a week. 
55% patients (50% cases, 60% controls) never consumed canned/preserved food and 36.67% 
(40% cases, 33.33% controls) reported occasional consumption. 
Milk consumption on a daily basis was reported in 43.33% of cases and 60% among controls 
whereas frequency of egg consumption was less than twice a week in 56.67% cases and 30% 
controls (Pearson Chi2 p value – 0.207). 
Most common oil used was Sunflower oil in 53.33% cases and 56.67% controls with no 
difference. 
Most common source of drinking water was treated water in 46.67% cases (33.33% in controls) 
which was not statistically significant (Pearson Chi2 p value – 0.293). 
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Variable Subgroup Cases Controls Pearson Chi2 p value 
Diet pattern Vegetarian 2 (6.67%) 2 (6.67%) 1.00 
 Non-vegetarian 28 
(93.33%) 
28 (93.33%)  
Meat consumption Daily 5 
(17.86%) 
3 (10.71%) 0.791 
 Alternate days 6 
(21.43%) 
5 (17.86%)  
 < twice a week 16 
(57.14%) 
18 (64.29%)  
 Occasional 1 (3.57%) 2 (7.14%)  
Predominant type of meat Chicken 22 
(78.57%) 
16 (57.14%)  
 Mutton 0 6 (21.43%) 0.791 
 Pork 1 (3.57%) 0  
 Beef  1 (3.57%) 0  
 Fish 4 
(14.29%) 
6 (21.43%)  
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Milk consumption Daily 13 
(43.33%) 
18 (60%) 0.294 
 Alternate days 2 (6.67%) 2 (6.67%)  
 < twice a week 4 
(13.33%) 
1 (3.33%)  
 Occasional 5 
(16.67%) 
7 (23.33%)  
 Never 6 (20%) 2 (6.67%)  
Canned/Preserved food Daily 1 (3.33%) 0 0.594 
 Alternate days 1 (3.33%) 0  
 < twice a week 1 (3.33%) 2 (6.67%)  
 Occasional 12 (40%) 10 (33.33%)  
 Never 15 (50%) 18 (60%)  
Egg consumption Daily 2 (6.67%) 1 (3.3%) 0.207 
 Alternate days 4 
(13.33%) 
10 (33.33%)  
 < twice a week 17 
(56.67%) 
9 (30%)  
 Occasional 5 
(16.67%) 
7 (23.33%)  
 Never 2 (6.67%) 3 (10%)  
Type of oil Coconut oil 2 (6.67%) 2 (6.67%) 0.320 
 Sunflower oil 16 17 (56.67%)  
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(53.3%) 
 Mustard oil 10 
(33.33%) 
6 (20%)  
 Vegetable oil 1 (3.33) 0  
 Others 1 (3.33) 5 (16.67%)  
Source of drinking water Borewell 6 (20%) 12 (40%) 0.293 
 Public water 
supply 
9 (30%) 8 (26.67%)  
 River 1 (3.33%) 0  
 Treated water 14 
(46.67%) 
10 (33.33%)  
Use of boiled water Always 10 
(33.33%) 
11 (36.67%) 0.884 
 Occasionally 3 (10%) 2 (6.67%)  
 Never 17 
(56.67%) 
17 (56.67%)  
 
 
HYGIENE 
There was no significant difference in bathing habits of cases and controls. 70% cases and 
66.67% controls bathed daily where as 26.67% cases and 33.33% controls bathed twice daily. 
Source of bathing water was from public water supply in 50% of cases (36.67% in controls) and 
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borewell in 43.3% of cases (60% controls). There was no statistically significant difference 
between cases and controls (Pearson Chi2 p value – 0.49). 
All patients used soap regularly and only one patient in the control group reported allergic 
reaction to soap. Frequency of hand washing was found to be similar in both case and control 
group (More than 5 times daily in 76.67% of cases vs 73.33% controls). 
Majority of cases (83.33%) and controls (70%) had a closed drainage system at home with no 
statistically significant difference. Household waste was mostly disposed safely by municipal 
waste collection (66.67% cases vs 63.33% controls). 
With regards to menstrual hygiene, majority used pads in both groups (92.59% in cases and 
100% in controls) with frequent change and no reuse.  
Dryness of skin was reported by 5 cases as compared to only 2 controls. However, this difference 
was not statistically significant (Pearson Chi2 p value – 0.228). Similarly, excessive sweating was 
reported by 7 cases as compared to 2 controls. This was also found to be statistically 
insignificant (Pearson Chi2 p value – 0.071). There was no history of frequent skin 
infections/lesions among the case or control group. 
Variable Subgroup Cases Controls Pearson Chi2 p value 
Source of bathing 
water 
Borewell 13 (43.33%) 18 (60%) 0.490 
 Public water 
supply 
15 (50%) 11 (36.67%)  
 Reservoir 1 (3.33%) 0  
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 River 1 (3.33%) 1 (3.33%)  
Frequency of 
bathing 
Twice daily 8 (26.67%) 10 (3.33%) 0.536 
 Daily 21 (70%) 20 (66.67%)  
 Once in 2-3 days 1 (3.33%) 0  
Frequency of hand 
washing 
> 5 times/day  23 (76.67%) 22 (73.33%) 0.952 
 2-5 times/day 6 (20%) 7 (23.33%)  
 < 2 times/day 1 (3.33%) 1 (3.33%)  
Drainage Open 5 (16.67%) 9 (30%) 0.222 
 Closed 25 (83.33%) 21 (70%  
Waste disposal Outside the 
house 
4 (13.33%) 5 (16.67%) 0.934 
 Open ground 6 (20%) 6 (20%)  
 Municipal 
collection 
20 (66.67%) 19 (63.33%)  
 
 
Variable Subgroup Cases Controls Pearson Chi2 p value 
Usage of sanitary 
napkin/cloth 
Sanitary napkin 25 (92.59%) 26 (100%) 0.157 
 Cloth 2 (7.41%) 0  
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Frequency of change 
of sanitary 
napkin/cloth 
Many times/day 25 (92.59%) 25 (96.15%) 0.225 
 Once daily 2 (7.41%) 0  
 Once in 2-3 days 0 1 (3.85%)  
Frequency of 
washing external 
genitalia 
Many times/day 28 (96.55%) 28 (96.55%) 1.00 
 Once daily 1 (3.33%) 1 (3.33%)  
Dryness of skin  5 (16.67%) 2 (6.67%) 0.228 
Excessive sweating  7 (23.33%) 2 (6.67%) 0.071 
 
 
BENIGN BREAST DISEASE COMPLAINTS 
The prevalence of mastalgia was found to be similar in the case group (23.33%) as compared to 
the control group (26.67%). 20% of cases gave history of breast lumps in the past as compared to 
10% of patients in the control group. However, this difference was not statistically significant 
(Pearson Chi2 p value – 0.278). 
History of nipple discharge was found in 13.33% of cases with no patients in the control group 
having these complaints. This was found to be statistically significant (Pearson Chi2 p value – 
0.038). 
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Variable Cases Controls Pearson Chi2 p value 
History of mastalgia 7 (23.33%) 8 (26.67%) 0.766 
History of nipple 
discharge 
4 (13.33%) 0 0.038 
History of breast 
lumps 
6 (20%) 3 (10%) 0.278 
 
 
ENVIRONMENT 
Most women in the case group were predominantly in the household environment (83.33%). 
Majority of patients in both the groups did not have any exposure to pets or animals (86.67% 
cases, 83.33% controls). 
 
Variable Subgroup Cases Controls Pearson Chi2 p value 
Environment Household 25 (83.33%) 11 (36.67%) 0.000 
 Work 5 (16.67%) 19 (63.33%)  
Exposure to 
pets/animals 
 4 (13.33%) 5 (16.67%) 0.718 
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HORMONAL FACTORS 
88.53% of women in the study were premenopausal (90% cases; 86.67% controls), whereas 
11.67% women were postmenopausal (Three cases and four controls). While majority of women 
in the case or control group did not use OCPs on a regular basis, regular use of OCPs was 
reported by 7 patients in the case group and 1 patient in the control group.  This difference was 
not statistically significant (Pearson Chi2 p value – 0.058). 
None of the patients had history of use of hormonal IUCDs. However, 3 patients in the case 
group gave history of hormonal therapy for infertility as compared to none in the control group. 
This difference was not statistically significant (Pearson Chi2 p value – 0.076). 
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Variable Subgroup Cases Controls Pearson Chi2 p value 
Regular usage of 
OCPs 
Daily 4 (13.33%) 0 0.058 
 Occasionally 3 (10%) 1 (3.33%)  
 Never 23 (76.67%) 29 (96.67%)  
Hormonal therapy 
for infertility 
 3 (10%) 0 0.076 
Regular steroid use  2 (6.67%) 0 0.150 
History of breast 
lumps 
 6 (20%) 3 (10%) 0.278 
 
 
HABITS 
None of the participants gave history of smoking, consumption of alcohol or tobacco. 
PREGNANCY 
Parity among cases varied from 1-4 with a mean of 2.13. Among controls, parity ranged from 1-
5, with a mean of 2.1. Two-sample t test did not show statistically significant difference between 
the means of the two groups (Two sample t-test p value = 0.8922). 
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The average spacing between births among cases was 48 months as compared to 44.35 months in 
controls. 
96.67% of patients received immunization in pregnancy in the case group as compared to 90% in 
the control group. 23.33% of patients were diagnosed with a medical comorbidity during 
pregnancy as compared to 13.33% in the control population. However, these observations did not 
show any statistically significant difference (Pearson Chi2 p value – 0.301, 0.317). None of the 
cases or controls received any postnatal immunization. 
 
Variable Cases Controls Pearson Chi2 p value 
Immunization in 
pregnancy 
29 (96.67%) 27 (90%) 0.301 
Comorbidities in 
pregnancy 
7 (23.33%) 4 (13.33%) 0.317 
 
Variable Case (Mean +/- S.D) Control (Mean +/- S.D) p value 
Parity 2.133 +/- 0.94 2.1 +/- 0.96 0.8922 
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COMORBIDITIES 
5 patients among cases and 3 patients among controls were known diabetics. 2 patients were 
diagnosed with TB in the past in the case group as compared to none in the control group. 2 
patients in the case group also gave history of contact with TB as compared to none in the 
control group. These differences were not statistically significant (Pearson Chi2 p value – 0.448, 
0.150, 0.150 respectively). There was no history of immunosuppressive disease among both 
cases and controls. Immunization status was complete in 36.67% of cases (56.6% controls) 
whereas 63.33% of cases and 36.67% of controls were unaware of their immunization status. 
Variable Cases Controls Pearson Chi2 p value 
DM 5 (16.67%) 3 (10%) 0.448 
TB 2 (6.67%) 0 0.150 
Contact with TB 2 (6.67%) 0 0.150 
 
 
Variable Subgroup Cases Controls Pearson Chi2 p value 
BCG vaccination Yes 13 (43.33%) 18 (60%) 0.099 
 No 0 2 (6.67%)  
 Unaware 17 (56.67%) 10 (33.3%)  
Immunization status Yes 11 (36.67%) 17 (56.67%) 0.067 
 No 0 2 (6.67%)  
 Unaware 19 (63.33%) 11 (36.67%)  
Table 7.23 
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AUTOIMMUNE SYMPTOMS 
23.33% of patients in the case group reported symptoms of joint pains as compared to 6.67% in 
the control group. 10% of patients in the case group (0% controls) reported skin lesions and 
3.33% of patients reported eye symptoms (0% controls). However, these differences were 
statistically insignificant (Pearson Chi2 p value – 0.071, 0.076, 0.313 respectively). There was no 
family history of autoimmune disease in both cases and controls. 
 
Variable Cases Controls Pearson Chi2 p value 
Joint pains 7 (23.33%) 2 (6.67%) 0.071 
Skin lesions 3 (10%) 0 0.076 
Eye symptoms 1 (3.33%) 0 0.313 
 
 
CLINICAL PROFILE 
Involvement of right breast (56.67%) was found to be more common than the left (43.33%). 
There were no patients with bilateral disease.  
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Patients mostly presented with history of breast lumps (96.67%) and pain (93.33%). 7 patients 
(23.3%) gave history of fever at the onset of symptoms. There was history of pus discharge in 
41.38% of patients. 76.67% of patients presented with complaints of skin changes. 
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Involvement was mostly restricted to a single quadrant (66.67%) and involved multiple 
quadrants only in 10 patients (33.33%). Distribution amongst different quadrants are shown in 
the figure below. 
 
 
 
The breast lumps were on an average measuring 5.62 cm x 7.02 cm. (Dimensions ranging from 
2-10 cm). 80% of breast lumps were firm in consistency with 20% being hard.  
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Majority of the lumps had restricted mobility as shown in the figure below 
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Presence of skin changes was noted in 76.67% and consisted of features such as erythema 
(82.61%) warmth (73.91%), skin ulceration (39.13%), discharging sinuses (36.67%), tenderness 
(47.83%), skin edema (34.78%) and abscess formation (39.13%). Axillary lymphadenopathy was 
noted in 50% of patients. 
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IMAGING CHARACTERISTICS 
Patients underwent evaluation with Ultrasonography, Mammogram or both. Modality of imaging 
used has been described in the figure below. 
 
 
 
 
ULTRASOUND CHARACTERISTICS 
The breast parenchyma in 89.47% patients was found to be predominantly fibroglandular 
whereas 10.53% had heterogeneous parenchyma. 9 patients (39.13%) had a discrete lesion which 
was mostly ill-defined (77.78%) and hypoechoic (55.56%).  
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52.17% of patients had evidence of collection which was hypoechoic (90.91%) with thick 
internal echoes (91.67%). Multiple sinus tracts were present in 47.83% of patients. There was 
evidence of surrounding inflammation in 47.62% and axillary lymphadenopathy was noted in 
39.13%. 
 
 
 
 
MAMMOGRAM CHARACTERISTICS 
Most common parenchymal pattern was heterogeneous density (75%) with one patient having 
scattered areas of fibroglandular density. Only one patient had a well-defined discrete lesion and 
equal density. One patient had focal asymmetry (25%) and one patient had global asymmetry 
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(25%) with the remainder showing no asymmetry. There was no evidence of architectural 
distortion or calcifications. 
 
MANAGEMENT 
Patients underwent either medical, surgical or combined modality of management. One patient 
did not follow up for therapy. 
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MEDICAL MANAGEMENT 
Medical management was in the form of low dose steroid therapy which was given in 82.76% of 
patients. This was given as sole modality of management in 58.3% and preoperatively in 41.66% 
patients. Response to both sole steroid therapy and preoperative steroids is illustrated below  
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SURGICAL MANAGEMENT 
Fifteen patients underwent surgical management (51.72%). Surgical management included 
Incision and drainage, Debridement, Excision and Mastectomy which is detailed in the figure 
below. 
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As of October 2017, fifteen patients had reviewed for follow up in OPD. There was evidence of 
disease progression in one patient on medical management who was planned for surgical 
debridement. Three patients had incomplete response to medical management with residual 
disease requiring re-initiation of steroid therapy. One patient showed initial response to medical 
management but relapsed after completing the course of steroids.  Disease recurrence was noted 
in 2 patients, both of whom were managed solely by surgical methods. Seven patients were 
disease free at the time of review and one patient developed disease in the contralateral breast 
after having been operated on the left breast.  
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8. DISCUSSION 
 
Granulomatous mastitis, which was earlier described as a rare chronic inflammatory disease of 
the breast is currently being seen more commonly in our institution. Retrospective analysis of 
data from our institution has shown an increasing trend over the years, as illustrated below. 
 
 
 
We undertook this study with an aim to elucidate the etiology of the granulomatous mastitis. As 
described above, we looked at the different theories that have been described in literature – 
Autoimmune, infectious, hormonal etiology. We also analyzed other risk factors with the help of 
the validated, structured questionnaire based on previously published literature and the basic 
pathogenesis of granulomatous inflammation. 
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Most of our patient population were young women with a mean age of 34 years with a wide 
range of 23-65 years. This was found to be similar to published literature. Unlike few published 
case reports and case series, all our cases were females and we did not have any male patients 
with granulomatous mastitis. Geographical distribution showed predominance of cases from 
West Bengal which is similar to the control group and reflects the larger number of patients from 
that region visiting our hospital every year.  
 
The primary objective was to study the role of infectious agents and autoimmunity in the role of 
causation of granulomatous mastitis. In our series, Cultures were positive in only eight patients 
(26.7%) for a bacterial organism whereas fungal, MGIT culture and Gene XPERT TB PCR did 
not show any growth. The organism cultured however, were thought to be either due to 
contamination of the sample during sample collection, transport or inoculation (Coagulase 
negative staphylococcus aureus, contaminants) or superadded hospital acquired bacterial 
infection (MRSA). One patient in our series was treated for Tuberculous lymphadenitis and 
spondyloarthritis with Antitubercular therapy for 8 months and presented with a painful breast 
lump with sinus discharging purulent material. Core biopsy however, did not show growth of 
acid fast bacilli on MGIT and Gene Xpert TB PCR. She was concomitantly diagnosed with 
multi-drug resistant tuberculous pleural effusion and was treated with second line ATT for the 
same. Despite harboring Mycobacteria, tissue from the breast did not reveal the presence of 
organism. Thus, tuberculosis is a rare etiology for granulomatous inflammation in the breast, 
even in a population with high incidence. 
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In order to look at the role of autoimmunity, we analyzed anti-nuclear antibodies which was used 
as a broad marker for autoimmunity in the serum of cases as well as controls. Only one patient in 
our series showed positivity for serum ANA. However, this patient was already diagnosed with 
Rheumatoid arthritis and was on treatment for the same.  
Serum Globulin levels and Immunoglobulin levels, in patients whose globulin levels were 
elevated were also measured. However, there was no evidence of hypergammaglobulinemia in 
any of the cases.  
Two patients were diagnosed with arthritis and one of them had also presented with multiple skin 
lesions suggestive of Erythema nodosum. However, both of them were ANA negative. 
Analysis of autoimmune symptoms such as history of joint pain, skin lesions, eye symptoms, 
prolonged fever, oral or genital ulcers and family history of autoimmune diseases was done 
between cases and controls. Though there was a higher number of cases than controls who gave 
history of joint pain, skin lesions and eye symptoms, this difference was not statistically 
significant. Hence, the possibility of a systemic autoimmune phenomenon causing 
granulomatous inflammation seems to be unlikely. 
One of the secondary objectives was to look for presence of other risk factors. This was 
categorized into breastfeeding practices, clothing habits, application of local substances, local 
trauma, dietary habits, hygiene practices, addictive habits, environmental exposure, hormonal 
factors, pregnancy-related factors and other illness-related factors.  
Most women from both groups breastfed from both sides and only three cases did not breastfeed 
on the diseased side. Between the two groups, there was a statistically significant difference in 
the duration of breastfeeding and history of washing hands before initiating breastfeeding. 
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Lactation-related problems such as mastitis, abscess, engorgement and cracked nipple were more 
among the case group, but the difference was not statistically significant.  
Comparison of clothing habits, local application, local trauma, dietary habits, hygiene practices 
and environmental factors between cases and controls did not reveal any significant difference to 
suggest a role in disease causation. Pregnancy-related factors and other illnesses did not seem to 
have a bearing on disease causation. 
Regular OCP use and history of hormonal therapy for infertility was found to be more in cases 
than controls which was however, was not statistically significant. None of the other hormonal 
factors analyzed seemed to be significantly different among the two groups.  
The other secondary objective was to establish the clinical profile of patients with granulomatous 
mastitis. Right breast was involved more commonly than the left and disease was mostly in the 
upper outer quadrant, as in other breast diseases due to the presence of more breast tissue in this 
quadrant. The most common presentation was painful breast lumps which were firm in 
consistency with restricted mobility. Skin changes suggestive of inflammation were noted in 
majority of these cases (76.7%). Half of the patients also had palpable axillary lymphadenopathy. 
There has been a paradigm shift in management of these patients from purely surgical therapy to 
combined therapy and even upfront medical therapy followed by reassessment and surgical 
intervention only in the setting of recurrence, relapse or partial response. Response to steroid 
therapy was noted to be varied with majority showing partial response. Three out of four patients 
who developed recurrence, underwent only surgical therapy with no administration of 
preoperative or postoperative steroids. 
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9. CONCLUSION 
 
There was no evidence of uncommon infections caused by bacterial, mycobacterial or fungal 
pathogens. Markers for systemic autoimmunity such as Serum ANA, Immunoglobulin levels did 
not show any positivity amongst our cases. There was no significant hyperprolactinemia in our 
cases. The role of other risk factors such as breastfeeding practices, clothing habits, application 
of local substances, local trauma, dietary habits, hygiene practices, habitual substance usage, 
environmental exposure, hormonal factors, pregnancy-related factors and other illness-related 
factors were also not found to be significant. The etiology of Granulomatous mastitis continues 
to be elusive. 
However, the investigators did recognize the possibility of a localized autoimmune phenomenon 
that was not analyzed as part of this study. Hence, we propose that further studies need to be 
done in this regard and intend to carry out the next study to look at immunohistochemical 
analysis for immunological cells such as T and B lymphocytes in the biopsy specimen to 
investigate localized autoimmune phenomenon. 
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ANNEXURE – I 
PATIENT INFORMATION SHEET 
ETIOLOGICAL EVALUATION OF IDIOPATHIC GRANULOMATOUS MASTITIS BY 
A PROSPECTIVE CASE CONTROL STUDY 
DEPARTMENT OF GENERAL & ENDOCRINE SURGERY 
CHRISTIAN MEDICAL COLLEGE, VELLORE 
PATIENT INFORMATION SHEET  
You are being invited to participate in a study to evaluate the factors that may be associated with 
the condition Idiopathic granulomatous mastitis. Thank you for agreeing to be part of this study.  
What is the background behind this study?  
Idiopathic granulomatous mastitis is a chronic inflammatory condition (Pain, swelling and 
redness) affecting the breasts. It commonly affects young women, usually within 5 years of 
childbirth and breastfeeding. The condition has a prolonged course often reappearing after 
treatment. Over the past few years, the number of patients presenting to CMCH, Vellore have 
been gradually increasing. The causative factors and mechanism of the disease is poorly 
understood.  
What is the purpose of the study?  
Among the many theories proposed, the most widely accepted mechanism is said to be increased 
proteinaceous secretion in the ducts of the breast due to hormonal imbalances. This causes 
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collection of secretions within the duct leading to perforation of the ducts and leakage into the 
breast tissue causing a inflammatory reaction. This reaction is believed to be an autoimmune 
phenomenon (reaction of the body to self). The other theories proposed are Smoking, Pregnancy, 
Childbirth and breastfeeding, Infection (Bacterial, TB, Fungi), Oral contraceptive pill use, 
Hyperprolactinemia (Increased levels of hormone prolactin involved in milk secretion), 
Autoimmunity (reaction of the body to self) and Ethnicity. The purpose of this study is to 
analyse the probable causative factors for Granulomatous mastitis and look at the demographic 
and clinic profile of the patients.  
If you take part what will you have to do?  
If you agree to participate in this study, you will be asked a few questions about your personal 
details (such as age, socioeconomic status, state of origin etc.,) and about your disease (such as 
duration, chief complaint, questions on risk factors etc.). You will be examined by the doctor and 
findings will be noted. We will be taking blood samples along with the routine samples using 
standard universal precautions for evaluation of markers to look at autoimmunity (Serum ANA, 
Specific autoantibodies, Globulins and Immunoglobulin levels) and Hyperprolactinemia (Serum 
prolactin). All other treatments that you are already on will be continued and your regular 
treatment protocol for the disease will not be changed due to this study.  
Can you withdraw from this study after it starts?  
Your participation in this study is entirely voluntary and you are also free to decide to withdraw 
permission to participate in this study. If you do so, this will not affect your usual treatment at 
this hospital in any way.  
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What will happen if you develop any study related injury?  
We do not expect any untoward event to occur due to the study as there will be no risk or 
intervention. The blood samples will be taken along with the routine samples.  
Will you have to pay for the blood test?  
The blood test taken from you will be performed free of cost for the purpose of this study.  
The regular diagnostic and treatment protocol (Biopsy, Routine bacterial staining and culture, 
AFB staining and culture, Fungal staining and culture) will be continued and the expenses will 
have to be met by you, according to the hospital regulations.  
Will your personal details be kept confidential?  
The results of this study will be published in a medical journal but you will not be identified by 
name in any publication or presentation of results. However, your medical notes may be 
reviewed by people associated with the study, without your additional permission, should you 
decide to participate in this study.  
If you have any further questions, please contact DR. , (Ph) or email:  
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ANNEXURE – II 
INFORMED CONSENT FORM 
Study Title: ETIOLOGICAL EVALUATION OF IDIOPATHIC GRANULOMATOUS 
MASTITIS BY A PROSPECTIVE CASE CONTROL STUDY  
Study Number:  
Participant’s name:  
Date of Birth / Age (in years):  
I_____________________________________________________________  
___________, daughter of ___________________________________  
(Please tick boxes) declare that  
(i)  I confirm that I have read and understood the information sheet dated ____________ 
for the above study and have had the opportunity to ask questions. [ ]   
(ii)  I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or legal rights 
being affected. [ ]   
(iii)  I understand that the study staff, the Ethics Committee and the regulatory authorities 
will not need my permission to look at my health records both in respect of the current 
study and any further research that may be conducted in relation to it, even if I withdraw 
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from the trial. I agree to this access. However, I understand that my identity will not be 
revealed in any information released to third parties or published. [ ]   
(iv)  I agree not to restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose(s). [ ]   
(v)  I agree to take part in the above study. [ ]   
 
1. Signature (or Thumb impression) of the Subject/Legally Acceptable Guardian 
 Date: _____/_____/______  
 
Signatory’s Name: _________________________________  
2. Signature of the Investigator: ________________________  
Date: _____/_____/______  
Study Investigator’s Name:  
3. Signature or thumb impression of the Witness: ___________________________  
Date: _____/_____/_______  
Name & Address of the Witness: ______________________________  
	   117	  
ANNEXURE – III 
CLINICAL RESEARCH FORM 
ETIOLOGICAL EVALUATION OF IDIOPATHIC GRANULOMATOUS MASTITIS BY 
A PROSPECTIVE CASE CONTROL STUDY 
STRUCTURED STUDY QUESTIONNAIRE 
 
PATIENT DEMOGRAPHICS  
Study Number:        Hospital Number:  
Contact no. (Landline with STD code):  
Contact no. (Mobile):  
Name:  
Address:  
 
Age at presentation:  
State of Origin:  
Socioeconomic score: 1. Occupation of the Head:  
2. Family Income per month:  
3. Education of the head:  
Total score:  
Socioeconomic scale (Modified Kupusamy scale):  
RISK FACTOR ANALYSIS BREASTFEEDING PRACTICES  
No. of children breastfed:  
Average duration of breastfeeding in all pregnancies:  
Currently breastfeeding: Yes/No    Duration of last breastfeeding:  
Breastfed last child: Yes/No     Time since last breastfed:  
	   118	  
Adequacy of breastfeeding: Always/Almost always/ Occasionally/ Never  
Frequency of breast feeding: On demand/periodically  
If periodically: Every 2 hours/ 5-10 times a day/ <5 times a day  
Side of Breastfeeding: Bilateral/Unilateral    If unilateral: Left/Right 
Reason for Unilateral breast feeding: Feeling of inadequate milk production/ Retracted nipple/ 
Cracked nipple/ Breast engorgement/ Breast Abscess or mastitis/Others__________________  
Use of breast pump/Expressed breast milk: Yes/ No  
History of cracked nipple during lactation: Yes/ No If yes, Managed by: Medical/Surgical  
 
History of Mastitis/abscesses during lactation: Yes/ No If yes, Managed by: Medical/Surgical  
History of breast engorgement: Yes/ No  If yes, Managed by: Medical/Surgical 
Cleaning of breast prior to breastfeeding: Yes/ No   
Washing hands prior to breastfeeding:     Yes/No  
Cleaning of breast after breastfeeding: Yes/ No        
Washing hands after breastfeeding: Yes/ No  
 
CLOTHING HABITS  
Usage of brassiere: Daily/ Only outside the house/ Occasionally/ Never  
Hours of usage of brassiere: Always/ <6 Hrs/ 6-12 Hrs/ >12 Hrs/ Others__________________  
Frequency of change of brassiere: Daily/ Once in 2-3 days/ Once a week/ 
Others______________  
Fitting of undergarments: Loose/Fitting/Tight  
Any allergic reactions to use of brassiere: Yes/ No  
Source of water used for washing: Borewell/ Public water supply/ Well/ Reservoir/ River/ 
Polluted water/ Others__________  
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LOCAL APPLICATION  
Regular application of talcum powder: Yes/ No  
Regular application of oil: Yes/ No  
Regular application of moisturiser: Yes/ No  
Regular application of turmeric powder: Yes/ No  
Regular use of deodorant/perfume: Yes/ No  
Regular application of any other substances: Yes/ No  
Any allergic reactions to application of any substances: Yes/ No  
TRAUMA  
Any history of trauma to the breast: Yes/ No  
Duration since trauma:___________________  
FOOD PRACTICES  
Predominant diet pattern: Vegetarian/ Non-vegetarian/ Mixed  
If non-vegetarian, Type of meat: Chicken/ Mutton/ Pork/ Beef/ Fish/ Others 
__________________ 
 Frequency of consumption of meat: Daily/ Alternate days/ < Twice a week/ Occasional/ Never  
Predominant cereal/ pulse based diet:  
Details:______________________  
Regular intake of canned/preserved foods/pickles: Daily/ Alternate days/ < Twice a week/ 
Occasional/ Never  
Regular intake of milk: Daily/ Alternate days/ < Twice a week/ Occasional/ Never  
Type of milk: Cow/ Buffalo/ Goat  
Boiled/ Raw milk  
Regular intake of eggs: Daily/ Alternate days/ < Twice a week/ Occasional/ Never  
Cooked/ Raw eggs 
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Type of Oil:  
Particular foods ingested during pregnancy/ lactation _________________________________  
Source of drinking/Cooking water: Borewell/ Public water supply/ Well/ Reservoir/ River/ 
Polluted water/ Others__________  
Use of boiled water: Always/ Occasionally/ Never  
HYGIENE AND PERSONAL HABITS  
Frequency of bathing: Twice daily/ Daily/ Once in 2-3 days/ Once a week/ 
Others______________  
Source of bathing water: Borewell/ Public water supply/ Well/ Reservoir/ River/ Polluted water/ 
Others__________ 
Usage of soap: Always/ Occasionally/ Never  
Any allergic reactions to soap: Yes/ No  
Frequency of hand washing: > 5 times/ 2-5 times/ <2 times  
Type of drainage system: Open/ Closed  
Waste disposal: Outside the house/ Open ground/ Municipal waste collection  
Excessive sweating: Yes/ No  
Frequent skin infections: Yes/No  
Dryness of skin: Yes/ No  
BENIGN BREAST COMPLAINTS  
Mastalgia: Yes/ No  
Nipple discharge: Yes/ No  
Breast lumps: Yes/ No  
HABITS  
Smoking: Yes/No  
Alcohol: Y/N 
Tobacco: Y/N  
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ENVIRONMENT  
Predominant work environment/Predominant household environment  
Exposure to pets/ Animals: Yes/ No  
MENSTRUAL AND HORMONAL FACTORS  
Age at Menarche:       Age at menopause:  
Regular/ Irregular periods      Usage of sanitary pads/ cloth  
Frequency of change of pads/cloth: Many times daily/ Once daily/ Once in 2-3 days/ Once a 
week/ Others______________  
Reuse of pads/cloth: Yes/ No  
Frequency of washing external genitalia: Many times daily/ Once daily/ Once in 2-3 days/ Once 
a week/ Others______________  
Regular oral contraceptive pill usage: Yes/ No  
Frequency: Daily/ Occasionally  
Type of OCP: Combination pills/ Progestin only pills/ Emergency pills/ Others______________  
Hormonal IUCD use: Yes/ No   Duration  
Infertility treatment: Yes/ No  
Steroid use: Yes/ No  
Galactorrhea: Yes/ No  
PREGNANCY  
Parity: Para ____ Living ____ Abortions____SB____ Neonatal/childhood deaths____  
Average spacing between births:     Last Child birth: 
Immunization during last pregnancy:  
Treatment during last pregnancy:  
Comorbidities during last pregnancy:  
Immunisation in the postnatal period:  
	   122	  
COMORBIDITES AND ILLNESSES  
DM: Yes/ No  
Immunosuppression: Yes/ No  
History of previous TB: Yes/ No  
History of contact with TB: Yes/ No     Other comorbidities:  
        Duration: 
Treatment history: ATT/ Immunosuppressants/Others  
Recent viral illnesses: Yes/ No  
BCG Vaccination: Yes/ No/ Unaware  
Immunization status: Complete / Incomplete/Unaware  
CLINICAL PROFILE  
PRESENTING COMPLAINTS  
Involved breast: Unilateral/Bilateral  If Unilateral, Side involved: Left/Right  
Breast Lump: Yes/ No     If yes Duration: 
Associated symptoms:  
Pain: Yes/ No       Duration: 
Fever: Yes/ No     Duration: 
Skin changes: Yes/ No     Duration: 
Warmth       Duration: 
Tenderness      Duration: 
Skin ulceration      Duration: 
Abscess formation      Duration: 
Erythema       Duration: 
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AUTOIMMUNE SYMPTOMS  
Joint pains/swelling: Yes/ No  
 
Skin Lesions: Yes/ No  If yes: Photosensitivity/Skin tightening/Vasculitic skin rash/Skin 
ulcers  
Eye symptoms: Yes/ No  If yes: Dryness of eyes/Redness and watering of eyes 
Prolonged fever: Yes/ No 
Mucosal ulcers: Yes/ No  If yes: Oral/Genital  
Other relevant symptoms:  
Family history of autoimmunity: Yes/ No  
 
EXAMINATION  
LOCAL EXAMINATION:  
Involved breast: Unilateral/Bilateral  If Unilateral, Side involved: Left/Right  
Quadrant of breast involved: UO / UI / LO / LI / Retroareolar  
Breast lump: Yes/ No  
Size: Consistency Soft / Firm / Hard  
Discharging sinus: Yes/ No    If yes : Colour of discharge 
Nipple discharge: Yes/ No    If yes : Colour of discharge 
Mobility Mobile/Fixed  
Inflammatory skin changes: Yes/ No  
Warmth  
Tenderness  
Skin edema  
Skin ulceration  
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Abscess formation  
Erythema  
Ipsilateral Axillary lymphadenopathy : Yes/ No  
 
PICTORICAL REPRESENTATION  
 
 
 
LABORATORY PARAMETERS  
Serum ANA: Positive/Negative  
Intensity: 1+/2+/3+  
Dilution:  
Specific autoantibody:  
Globulin levels:  
Immunoglobulins: IgM     IgG    IgA 
Serum prolactin:  
Bacterial culture:  
MGIT culture:  
Fungal culture:  
Gene XPERT TB PCR: 
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IMAGING  
Modality: USG / Mammogram / Others  
BIRADS score: 0 / 1 / 2 / 3 / 4 / 5  
Quadrants involved: UO / UI / LO / LI / Retroareolar  
Specific features:  
 
MANAGEMENT 
Medical/Surgical/Medical + Surgical  
Pre-op/Post-op steroids      Duration:  
Response to steroids: Complete/Partial/No response  
Surgery: I&D/Debridement/WLE  
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ANNEXURE IV – LIST OF VARIABLES 
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ANNEXURE V - DATASHEET 
